PMV Pharmaceuticals, Inc. (PMVP) Reports 48% Response Rate in Ovarian Cancer Trial

PMV Pharmaceuticals reported Phase 2 trial results for its ovarian cancer treatment, showing a 48% response rate in 65 patients and a 36% rate in 168 evaluable patients. The company plans to submit a New Drug Application in Q1 2027.

Original reporting
Published Nov 20, 2026, 3:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 3:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PMV Pharmaceuticals, Inc. (PMVP) Reports 48% Response Rate in Ovarian Cancer Trial — source image
Decision brief

The 30-second read

$PMVPBullishMed
01

Why it matters

The disclosed ORR of 48% in a hard‑to‑treat population is a strong efficacy signal that could accelerate the upcoming NDA submission.

02

Market read

First report of pivotal trial data; potential catalyst for share price ahead of regulatory filing.

03

What to watch

Small patient cohort and lack of comparator arm could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: post‑release today

Background

PMV Pharmaceuticals is a clinical‑stage biotech focused on oncology therapies.

Company-level read

Ticker impact

$PMVPBullishHigh confidence
Context

Phase 2 trial reports 48% ORR in platinum‑resistant ovarian cancer patients, new data not previously disclosed.

Expected impact

likely upward pressure as investors price in potential approval and market opportunity.

Evidence & confidence

First public disclosure of pivotal efficacy data; biotech stocks typically react strongly to such news.

Market effects

May lift sentiment in the oncology biotech sector.

Limited to US biotech investors.

Modest, primarily affecting niche oncology investors.

Counterpoint

Skeptics may question durability of response and regulatory risk.

Key entities

  • PMV Pharmaceuticals, Inc.

    Clinical‑stage oncology biotech.

Related articles

$PMVPMedAI 9/10

PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated…

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PMV Pharmaceuticals Announces Promising Updated Data From the PYNNACLE Phase 2 Pivotal Trial of Rezatapopt Monotherapy in Patients With TP53 Y220C-Mutated Advanced Solid Tumors • 48% confirmed overall response rate (ORR) with a 10.4-month median duration of response

$PMVPMed

PMV Pharmaceuticals 3Q 2026: EPS ($0.52) — 10-Q Summary

PMV Pharmaceuticals reported a wider net loss of $34.37M in Q3 2026, with EPS at ($0.52), due to warrant remeasurement loss and offering costs. The company completed enrollment for a Phase 2 trial of rezatapopt and plans to submit an NDA in Q1 2027. Cash reserves totaled $108.5M, expected to last into Q1 2028.

$PMVPMedAI 8/10

PMV Pharmaceuticals Reports Q3 2026 Results, $108.5M in Cash and Securities

PMV Pharmaceuticals reported a Q3 2026 net loss of $34.4M, with $108.5M in cash. It expects cash to last into Q1 2028. The company completed enrollment for its Phase 2 ovarian cancer trial and plans to submit a rezatapopt NDA in Q1 2027. Research and development expenses were $16.1M, with general and administrative expenses at $4.0M. The company appointed new board members and a chief commercial officer.

$PMVPMed

PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate

PMV Pharmaceuticals, Inc. (PMVP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights • Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026 • Announced closing of oversubscribed $50 million public offering of sec

$PMVPMed

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PMV Pharmaceuticals (Nasdaq: PMVP) reported Q2 2026 results and clinical updates. Enrollment for the Phase 2 monotherapy primary analysis in its PYNNACLE trial for rezatapopt in TP53 Y220C ovarian cancer is complete. The company plans an NDA for accelerated approval in Q1 2027. Cash, cash equivalents and marketable securities were $79.4M at June 30, 2026, with net loss $18.1M.